ProQR Therapeutics NV
NASDAQ:PRQR

Watchlist Manager
ProQR Therapeutics NV Logo
ProQR Therapeutics NV
NASDAQ:PRQR
Watchlist
Price: 1.41 USD -1.4% Market Closed
Market Cap: 149.3m USD

Wall Street
Price Targets

PRQR Price Targets Summary
ProQR Therapeutics NV

Wall Street analysts forecast PRQR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PRQR is 9.69 USD with a low forecast of 4.04 USD and a high forecast of 15.75 USD.

Lowest
Price Target
4.04 USD
187% Upside
Average
Price Target
9.69 USD
587% Upside
Highest
Price Target
15.75 USD
1 017% Upside
ProQR Therapeutics NV Competitors:
Price Targets
IONS
Ionis Pharmaceuticals Inc
92% Upside
SIGHT
Gensight Biologics SA
72% Upside
2162
KeyMed Biosciences Inc
34% Upside
251120
Bio-FD&C Co Ltd
54% Upside
AMGN
Amgen Inc
6% Upside
2696
Shanghai Henlius Biotech Inc
34% Downside
300685
Amoy Diagnostics Co Ltd
33% Upside

Revenue
Forecast

Revenue Estimate
ProQR Therapeutics NV

For the last 8 years the compound annual growth rate for ProQR Therapeutics NV's revenue is 34%. The projected CAGR for the next 3 years is -9%.

34%
Past Growth
-9%
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Operating Income
Forecast

Operating Income Estimate
ProQR Therapeutics NV

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

Net Income Estimate
ProQR Therapeutics NV

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-52%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PRQR's stock price target?
Price Target
9.69 USD

According to Wall Street analysts, the average 1-year price target for PRQR is 9.69 USD with a low forecast of 4.04 USD and a high forecast of 15.75 USD.

What is ProQR Therapeutics NV's Revenue forecast?
Projected CAGR
-9%

For the last 8 years the compound annual growth rate for ProQR Therapeutics NV's revenue is 34%. The projected CAGR for the next 3 years is -9%.

Back to Top